NewAmsterdam Pharma Company N.V.
NAMS
$16.34
$0.311.93%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -241.60M | -198.92M | -229.40M | -228.69M | -176.94M |
| Total Depreciation and Amortization | 113.00K | 75.00K | 61.00K | 55.00K | 49.00K |
| Total Amortization of Deferred Charges | -227.00K | -- | -- | -- | -- |
| Total Other Non-Cash Items | 115.82M | 60.04M | 61.98M | 68.37M | 29.80M |
| Change in Net Operating Assets | -32.67M | -15.36M | -21.27M | -3.69M | 5.87M |
| Cash from Operations | -158.56M | -154.16M | -188.63M | -163.96M | -141.22M |
| Capital Expenditure | -672.00K | -672.00K | -606.00K | -402.00K | -24.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -62.18M | -- | -- | -- | -- |
| Cash from Investing | -62.85M | -672.00K | -606.00K | -402.00K | -24.00K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 859.73M | 403.10M | 403.22M | 404.90M | 8.91M |
| Repurchase of Common Stock | -989.00K | -989.00K | -989.00K | -989.00K | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -540.00K | -515.00K | -515.00K | -515.00K | -- |
| Cash from Financing | 659.51M | 202.90M | 203.02M | 204.70M | 8.91M |
| Foreign Exchange rate Adjustments | -6.80M | 6.36M | 215.00K | -506.00K | 5.05M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 431.29M | 54.42M | 14.00M | 39.84M | -127.28M |